Physician profile
George James
NPI 1629054184
$8,290.60
in general payments reported to CMS, 2019-2025
37 companies · $1,440 in 2025
The $1,440 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $875 · 2020: $677 · 2021: $1,014 · 2022: $1,615 · 2023: $1,027 · 2024: $1,643 · 2025: $1,440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,003 · Education: $84.99 · Travel and Lodging: $21.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,003.11 |
| Education | $84.99 |
| Travel and Lodging | $21.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $1,602.81 | 2019-2025 | Biomonitor, Amvia Edge |
| Medtronic, INC. | $1,199.82 | 2021-2024 | Micra |
| Actelion Pharmaceuticals US, INC. | $1,047.05 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Abbott Laboratories | $833.96 | 2019-2025 | Aveir, Cardiomems, Mitraclip |
| Novartis Pharmaceuticals Corporation | $423.77 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $373.87 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $364.15 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $256.04 | 2019-2025 | Jardiance |
| Pfizer INC. | $253.19 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $250.22 | 2019-2025 | Farxiga, Lokelma |
| Merck Sharp & Dohme LLC | $207.91 | 2021-2025 | Verquvo, Winrevair |
| Heartflow, INC. | $191.79 | 2019-2024 | |
| Boston Scientific Corporation | $146.63 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor |
| Zoll Respicardia, INC. | $138.78 | 2021 | |
| Amgen INC. | $112.96 | 2019-2025 | Repatha, Repatha |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $110.05 | 2023-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Sanofi-Aventis U.S. LLC | $81.12 | 2019-2024 | |
| Novo Nordisk INC | $76.13 | 2024-2025 | Wegovy, Ozempic |
| Itamar Medical INC | $75.00 | 2023 | Watchpatone |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $65.72 | 2024-2025 | Lifevest |
| United Therapeutics Corporation | $58.56 | 2019-2022 | |
| Teleflex LLC | $48.51 | 2019 | |
| Philips North America LLC | $43.66 | 2025 | Extended Holter |
| Bayer Healthcare Pharmaceuticals INC. | $36.12 | 2025 | |
| Azurity Pharmaceuticals, INC. | $34.27 | 2025 | Edarbi |
| Scpharmaceuticals INC. | $33.03 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $32.39 | 2021 | |
| Terumo Medical Corporation | $29.74 | 2024 | R2p Misago, Metacross Otw, Azur Cx Detachable |
| Vanda Pharmaceuticals INC. | $26.06 | 2025 | Fanapt |
| Ethicon US, LLC | $25.23 | 2025 | Vistaseal |
| Glaxosmithkline, LLC. | $24.35 | 2025 | Arexvy, Shingrix |
| Avinger INC. | $23.58 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $23.54 | 2023 | Inpefa |
| Amarin Pharma, INC. | $14.38 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.06 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.15 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$201,894.80 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.